Treatment of pancreatic cancer with a combination of irinotecan (CPT-11) and gemcitabine: A multicenter phase II study by the Greek Cooperative Group for Pancreatic Cancer

Annals of Oncology

Volumn 14, Issue 3, 2003, Pages 388-394

  Stathopoulos, G P ^a   Rigatos, S K ^a   Dimopoulos, M A ^b   Giannakakis, T ^c   Foutzilas, G ^d   Kouroussis, C ^e   Janninis, D ^c   Aravantinos, G ^c   Androulakis, N ^e   Agelaki, S ^e   Stathopoulos, J G ^a   Georgoulias, V ^e  

^a Errikos Dunant Hospital   (Greece)

^b ALEXANDRA HOSPITAL   (Greece)

^c Agii Anargyri Anticancer Hospital of Athens   (Greece)

^d AHEPA UNIVERSITY HOSPITAL   (Greece)

^e UNIVERSITY HOSPITAL OF HERAKLION   (Greece)

Author keywords

Combination; Gemcitabine; Irinotecan; Pancreatic cancer

Indexed keywords

ANALGESIC AGENT; ANTIBIOTIC AGENT; CAMPTOTHECIN DERIVATIVE; CISPLATIN; DOCETAXEL; DOXORUBICIN; FLUOROURACIL; FOLINIC ACID; GEMCITABINE; HEMOPOIETIC GROWTH FACTOR; IRINOTECAN; MITOMYCIN C; NARCOTIC AGENT; ONDANSETRON; OPIATE; OXALIPLATIN; RECOMBINANT ERYTHROPOIETIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; RUBITECAN; TOPOTECAN;

ADULT; AGED; ANEMIA; ARTICLE; ASTHENIA; BLOOD TRANSFUSION; BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PAIN; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG RESPONSE; FEBRILE NEUTROPENIA; FEMALE; GASTROINTESTINAL SYMPTOM; GRANULOCYTOPENIA; GREECE; HEALTH CARE ORGANIZATION; HUMAN; INFECTION; MALE; MUCOSA INFLAMMATION; MULTICENTER STUDY; NEUTROPENIA; PANCREAS CANCER; PATIENT COMPLIANCE; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; SEPSIS; THROMBOCYTOPENIA; UPPER GASTROINTESTINAL BLEEDING; WEIGHT GAIN; XEROSTOMIA;

AGED; ANEMIA; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CAMPTOTHECIN; DEOXYCYTIDINE; DISEASE PROGRESSION; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASM METASTASIS; NEUTROPENIA; PAIN; PANCREATIC NEOPLASMS; SURVIVAL ANALYSIS; THROMBOCYTOPENIA; TREATMENT OUTCOME;

EID: 12244297140     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdg109     Document Type: Article

References (30)

1. Schein PS. The role of chemotherapy in the management of gastric and pancreatic carcinomas. Semin Oncol 1985; 12 (Suppl 6): 49-60.
2. Schnall SF, Mac Donald JS. Chemotherapy of adenocarcinoma of the pancreas. Semin Oncol 1996; 23: 220-228.
3. Carter SK, Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev 1975; 2: 193-214.
4. Schein PS, Lavin PT, Moertel CG et al. Randomized phase II trial of adriamycin, methotrexate and actinomycin-D in advanced measurable pancreatic carcinoma. Cancer 1978; 42: 19-23.
5. Bitran JD, Desser RR, Kozloff MF et al. Treatment of metastatic pancreatic and gastric adenocarcinoma with 5-FU, adriamycin and mitomycin (FAM). Cancer Treat Rep 1979; 83: 2049-2055.
6. Wiggans RG, Walley PV, MacDonald JS et al. Phase II trial of streptozotocin, mitomycin-C and 5-fluorouracil (SMF) in the treatment of advanced pancreatic cancer. Cancer 1978; 41: 387-390.
7. Moertel CG, Fryta KS, Hahn RG et al. Therapy of locally unresectable pancreatic carcinomas: a randomized comparison of high dose (6000 Rads) radiation alone, moderate dose radiation (4000 Rads + 5-fluorouracil) and high dose radiation + 5-fluorouracil. The Gastrointestinal Tumor Study Group. Cancer 1981; 48: 1705-1710.
8. Hidalgo M, Castelliano D, Paz-Ares L et al. Phase I-II study of gemcitabine and fluorouracil as a continuous infusion in patients with pancreatic cancer. J Clin Oncol 1999; 17: 585-592.
9. Burris III HA, Moore MJ, Anderson J et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreas cancer: a randomized trial. J Clin Oncol 1997; 15: 2403-2413.
10. Rothenberg ML, Sharm A, Weiss GR et al. Phase I trial of paclitaxel and gemcitabine administered every 2 weeks in patients with refractory solid tumors. Ann Oncol 1998; 9: 733-738.
11. Androulakis N, Kouroussis Ch, Dimopoulos MA et al. Treatment of pancreatic cancer with docetaxel and granulocyte colony-stimulating factor: a multicenter phase II study. J Clin Oncol 1999; 17: 1779-1785.
12. Stathopoulos GP, Mavroudis D, Tsavaris N et al. Treatment of pancreatic cancer with a combination of docetaxel, gemcitabine and granulocyte colony-stimulating factor: a phase II study of the Greek Cooperative Group for Pancreatic Cancer. Ann Oncol 2001; 12: 101-103.
13. Schwartz CM, Zhan GZ, Szrajer L et al. Evaluation of gemcitabine and irinotecan (CPT-11) as single agents and combination in solid tumors using an ex-vivo ATP assay. Proc Am Soc Clin Oncol 2001; 20: 98 (Abstr 2143).
14. Wagener DJT, Verdonk HER, Dirix LY et al. Phase II trial of CPT-11 in patients with advanced pancreatic cancer. An EORTC Early Clinical Trials Group study. Ann Oncol 1995; 6: 129-133.
15. Kostandoulakis MM, Antonakis PT, Tsibloulis BG et al. A phase II study of 9-nitro-camptothecin in patients with advanced pancreatic adenocarcinoma. Cancer Chemother Pharmacol 2001; 48: 417-420.
16. Miller AB, Hoogstraten BB, Staquet M et al. Reporting results of cancer treatment. Cancer 1981; 47: 207-217.
17. Donehower RC, Abeloff MD, Perry MC. Response criteria. In Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE (eds): Clinical Oncology. New York, NY: Churchill Livingston 1995; 201-208.
18. Casper ES, Green MR, Kelsen DP. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12: 29-34.
19. Carmichael J, Fink U, Russel RCG et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1996; 73: 101-106.
20. Scher RM, Kosierowski R, Lusch C et al. Phase II trial of topotecan in advanced or metastatic adenocarcinoma of the pancreas. Invest New Drugs 1996; 13: 347-351.
21. Bruckuer H, Barzdins A, Humel P et al. Irinotecan combined with gemcitabine, 5-FU (5-fluorouracil), LV (leucovorin) and cisplatin (G-FLIP) is an effective and non-crossresistant regimen for refractory metastatic adenocarcinoma of the exocrine pancreas. Metastatic pancreatic cancer (MPAC). Proc Am Soc Clin Oncol 2001; 20: 155a (Abstr 615).
22. Max C, Rocha Lima S, Savarese D et al. Irinotecan plus gemcitabine reduces both radiographic and CA 19-9 tumor marker responses in patients with previously untreated advanced pancreatic cancer. J Clin Oncol 2002; 20: 1182-1191.
23. Heinemann V, Wilke H, Mergenthaler HG et al. Gemcitabine and cisplatin in the treatment of advanced or metastatic pancreatic cancer. Ann Oncol 2000; 11: 1399-1403.
24. Colucci G, Riccardi F, Ginliani F et al. Randomized trial of gemcitabine alone or with cisplatin in advanced pancreatic cancer: a phase II multicenter study of the Southern Italy Oncology Group. Proc Am Soc Clin Oncol 1999; 18: 250a (Abstr 961).
25. Alberts SR, Townley PM, Goldberg RM et al. Gemcitabine and oxaliplatin for patients with advanced or pancreatic metastatic cancer: a North Central Cancer Treatment Group (NCCTG) phase I study. Ann Oncol 2002; 13: 553-557.
26. Halford S, Yip D, Karapetis CS et al. A phase II study evaluating tolerability and efficacy of Caelyx (liposomal doxorubicin Doxil) in the treatment of unresectable pancreatic carcinoma. Ann Oncol 2001; 12: 1399-1402.
27. Alberts SR, Erlichman C, Sloan J et al. Phase I trial of gemcitabine and CPT-11 given weekly for four weeks every six weeks. Ann Oncol 2001; 12: 627-631.
28. Berlin JD, Catalano P, Thomas JP et al. Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group trial E2297. J Clin Oncol 2002; 20: 3270-3275.
29. Lutz MP, Ducreux M, Wagener T et al. Docetaxel/gemcitabine or docetaxel/cisplatin in advanced pancreatic carcinoma: a randomized phase II study of the EORTC-GI group. Proc Am Soc Clin Oncol 2002; 21: 125a (Abstr 498).
30. Di Costanzo F, Sdrobolini A, Carlini P et al. Gemcitabine (GEM) alone or in combination with 5-FU continuous infusion (CI) in the treatment of advanced pancreatic Cancer (APC): a GOIRC randomized phase II trial. Proc Am Soc Clin Oncol 2001; 20: 154a (Abstr 612).